Haplotypes covering the TNFSF10 gene are associated with bronchial asthma

Pediatric Allergy and Immunology

Volumn 22, Issue 1 PART 1, 2011, Pages 25-30

  Weckmann, Markus ^a   Kopp, Matthias Volkmar ^a   Heinzmann, Andrea ^a   Mattes, Joerg ^b,c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c JOHN HUNTER CHILDREN S HOSPITAL   (Australia)

Author keywords

Allergy; Asthma; Trail

Indexed keywords

TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADOLESCENT; ADULT; ALLELE; ARTICLE; ASTHMA; CAUCASIAN; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GERMANY; HAPLOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ALLELES; ASTHMA; CHILD; CHILD, PRESCHOOL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 78851472074     PISSN: 09056157     EISSN: 13993038     Source Type: Journal    
DOI: 10.1111/j.1399-3038.2010.01027.x     Document Type: Article

References (40)

1. Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006: 368: 733-43.
2. Kay AB. Allergy and allergic diseases. First of two parts. N Engl J Med 2001: 344: 30-7.
3. Lloyd C. Chemokines in allergic lung inflammation. Immunology 2002: 105: 144-54.
4. Stick SM, Holt PG. The airway epithelium as immune modulator: the LARC ascending. Am J Respir Cell Mol Biol 2003: 28: 641-4.
5. Weckmann M, Collison A, Simpson JL, et al. Critical link between TRAIL and CCL20 for the activation of TH2 cells and the expression of allergic airway disease. Nat Med 2007: 13: 1308-15.
6. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995: 3: 673-82.
7. Wang Q, Ji Y, Wang X, Evers BM. Isolation and molecular characterization of the 5'-upstream region of the human TRAIL gene. Biochem Biophys Res Commun 2000: 276: 466-71.
8. Kikuchi S, Miyagishi R, Fukazawa T, Yabe I, Miyazaki Y, Sasaki H. TNF-related apoptosis inducing ligand (TRAIL) gene polymorphism in Japanese patients with multiple sclerosis. J Neuroimmunol 2005: 167: 170-4.
9. Tomasetti M, Andera L, Alleva R, Borghi B, Neuzil J, Procopio A. Alpha-tocopheryl succinate induces DR4 and DR5 expression by a p53-dependent route: implication for sensitisation of resistant cancer cells to TRAIL apoptosis. FEBS Lett 2006: 580: 1925-31.
10. Marinescu VD, Kohane IS, Riva A The MAPPER database: a multi-genome catalog of putative transcription factor binding sites. Nucleic Acids Res 2005;33:D91-7.
11. Gray H, Sorensen E, Hunt J, Ober C. Three polymorphisms in the 3' UTR of the TRAIL (TNF-related apoptosis-inducing ligand) gene. Genes Immun 2001: 2: 469-70.
12. Sasieni PD. From genotypes to genes: doubling the sample size. Biometrics 1997: 53: 1253-61.
13. Zhao JH, Sham PC. Faster haplotype frequency estimation using unrelated subjects. Hum Hered 2002: 53: 36-41.
14. Becker T, Knapp M. Maximum-likelihood estimation of haplotype frequencies in nuclear families. Genet Epidemiol 2004: 27: 21-32.
15. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008: 8: 782-98.
16. Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 2007: 39: 1462-75.
17. Liu W, Liang Q, Balzar S, Wenzel S, Gorska M, Alam R. Cell-specific activation profile of extracellular signal-regulated kinase 1/2, Jun N-terminal kinase, and p38 mitogen-activated protein kinases in asthmatic airways. J Allergy Clin Immunol 2008: 121: 893-902. e2.
18. Duan W, Chan JH, McKay K, et al. Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am J Respir Crit Care Med 2005: 171: 571-8.
19. Duan W, Chan JH, Wong CH, Leung BP, Wong WS. Anti-inflammatory effects of mitogen-activated protein kinase kinase inhibitor U0126 in an asthma mouse model. J Immunol 2004: 172: 7053-9.
20. Kwak YG, Song CH, Yi HK, et al. Involvement of PTEN in airway hyperresponsiveness and inflammation in bronchial asthma. J Clin Invest 2003: 111: 1083-92.
21. Das DK, Al-Ayadhy B, Ajrawi MT, et al. Cytodiagnosis of nipple discharge: a study of 602 samples from 484 cases. Diagn Cytopathol 2001: 25: 25-37.
22. Howard TD, Koppelman GH, Xu J, et al. Gene-gene interaction in asthma: IL4RA and IL13 in a Dutch population with asthma. Am J Hum Genet 2002: 70: 230-6.
23. Kabesch M, Schedel M, Carr D, et al. IL-4/IL-13 pathway genetics strongly influence serum IgE levels and childhood asthma. J Allergy Clin Immunol 2006: 117: 269-74.
24. Gao PS, Heller NM, Walker W, et al. Variation in dinucleotide (GT) repeat sequence in the first exon of the STAT6 gene is associated with atopic asthma and differentially regulates the promoter activity in vitro. J Med Genet 2004: 41: 535-9.
25. Rosa-Rosa L, Zimmermann N, Bernstein JA, Rothenberg ME, Khurana Hershey GK, Izuhara K. The R576 IL-4 receptor alpha allele correlates with asthma severity [Atopy and interleukin-4 receptor]. J Allergy Clin Immunol 1999: 104: 1008-14.
26. Beghe B, Barton S, Rorke S, et al. Polymorphisms in the interleukin-4 and interleukin-4 receptor alpha chain genes confer susceptibility to asthma and atopy in a Caucasian population. Clin Exp Allergy 2003: 33: 1111-7.
27. Konstantinidis AK, Barton SJ, Sayers I, et al. Genetic association studies of interleukin-13 receptor alpha1 subunit gene polymorphisms in asthma and atopy. Eur Respir J 2007: 30: 40-7.
28. Lee SH, Shin MS, Kim HS, et al. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res 1999: 59: 5683-6.
29. Fisher M, Virmani A, Wu L, et al. Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res 2001: 7: 1688-97.
30. Lee S, Shin M, Kim H, et al. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene 2001: 20: 399-403.
31. Shin M, Kim H, Lee S, et al. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res 2001: 61: 4942-6.
32. Teng MS, Brandwein-Gensler MS, Teixeira MS, Martignetti JA, Duffey DC. A study of TRAIL receptors in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2005: 131: 407-12.
33. Park W, Lee J, Shin M, et al. Inactivating mutations of KILLER/DR5 gene in gastric cancers. Gastroenterology 2001: 121: 1219-25.
34. Wolf S, Mertens D, Pscherer A, et al. Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer. Int J Cancer 2006: 118: 1831-5.
35. Dechant MJ, Fellenberg J, Scheuerpflug CG, Ewerbeck V, Debatin KM. Mutation analysis of the apoptotic "death-receptors" and the adaptors TRADD and FADD/MORT-1 in osteosarcoma tumor samples and osteosarcoma cell lines. Int J Cancer 2004: 109: 661-7.
36. Martinez-Ferrandis JI, Rodriguez-Lopez R, Milne RL, et al. Polymorphisms in TRAIL receptor genes and risk of breast cancer in Spanish women. Cancer Biomark 2007: 3: 89-93.
37. Liu L, Tanaka H, Ito K, et al. Absence of gene mutation in TRAIL receptor 1 (TRAIL-R1) and TRAIL receptor 2 (TRAIL-R2) in chronic myelogenous leukemia and myelodysplastic syndrome, and analysis of mRNA Expressions of TRAIL and TRAIL-related genes in chronic myelogenous leukemia. Acta Haematol 2005: 113: 113-23.
38. Pai S, Wu G, Ozören N, et al. Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res 1998: 58: 3513-8.
39. Zerafa N, Westwood JA, Cretney E, et al. Cutting edge: TRAIL deficiency accelerates hematological malignancies. J Immunol 2005: 175: 5586-90.
40. Shastry BS. SNPs in disease gene mapping, medicinal drug development and evolution. J Hum Genet 2007: 52: 871-80.